# A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

> **NCT03800836** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 139 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Ipatasertib
- **DRUG:** Paclitaxel
- **DRUG:** Atezolizumab
- **DRUG:** Nab-Paclitaxel
- **DRUG:** AC

## Key facts

- **NCT ID:** NCT03800836
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-13
- **Primary completion:** 2022-03-16
- **Final completion:** 2022-03-16
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03800836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03800836, "A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03800836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*